- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04879485
Prehospital Transfusion Strategy in Bleeding Patients
Prehospital Plasma or Red Blood Cell Transfusion Strategy in Major Bleeding; PRIEST Trial
The aim of study is to compare clinical and biochemical effect of three different transfusion strategies among patients with major hemorrhage requiring prehospital transfusion.
A) Present prehospital standard treatment including a mixture of plasma and Red blood cell transfusion (RBC) transfusion B) Red blood cell transfusion (RBC) only C) Plasma transfusion only
Hypothesis:
- Transfusion strategy including a mixture of RBC and plasma is superior as compared with only plasma or only RBC strategy in terms of initial treatment of circulatory shock (expressed as base deficit).
- Endothelial function and ability of clot formation is preserved to a greater extent in patients receiving plasma.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Rationale for the study:
The warranted clinical question to be unsolved is whether initial pre-hospital transfusion in bleeding patients should base on a strategy including plasma, RBC or combination of both.
Despite possible benefits, allogenic blood product are associated with side effects and pose significant logistic challenges in the prehospital environment. So far, a majority of the present knowledge is based on retrospective evaluations or clinical trials without relevant control groups.
Studietype
Registrering (Forventet)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Christian Fenger-Eriksen, PhD
- Telefonnummer: +45 7846 6912
- E-post: christian.fenger-eriksen@viborg.rm.dk
Studiesteder
-
-
-
Aarhus, Danmark
- Rekruttering
- Danish Air Ambulance
-
Ta kontakt med:
- Christian Fenger-Eriksen
-
-
Midtjylland
-
Silkeborg, Midtjylland, Danmark, 8600
- Har ikke rekruttert ennå
- Aarhus Universityhospital
-
Ta kontakt med:
- Christian Fenger-Eriksen
- Telefonnummer: 26362416
- E-post: christian.fenger-eriksen@viborg.rm.dk
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Major bleeding requiring prehospital transfusion
Exclusion Criteria:
- Transfusion with blood products already initiated
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Ingen inngripen: Standard transfusion
Includes standard transfusion with a mixture of red blood cells and plasma
|
|
Aktiv komparator: Plasma
Transfusion with plasma
|
Compare two different transfusion strategies against standard transfusion regimen
|
Aktiv komparator: Red Blood cells
Transfusion with red blood cells
|
Compare two different transfusion strategies against standard transfusion regimen
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Base deficit
Tidsramme: At hospital arrival (with in 1 hour)
|
Arterial-gas analysis upon arrival with parameter base deficit as primary outcome
|
At hospital arrival (with in 1 hour)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
30 days mortality
Tidsramme: mortality within 30 days
|
Mortality, follow up in patient records
|
mortality within 30 days
|
Activated Partial Thromboplastin Time (APTT)
Tidsramme: At hospital arrival (with in 2 hours)
|
Plasma sample analysed; APTT
|
At hospital arrival (with in 2 hours)
|
Endogenous thrombin potential (ETP)
Tidsramme: At hospital arrival (with in 2 hours)
|
Plasma sample analysed; thrombin generation assay
|
At hospital arrival (with in 2 hours)
|
International Normalized Ratio (INR)
Tidsramme: At hospital arrival (with in 2 hours)
|
Plasma sample analysed; INR
|
At hospital arrival (with in 2 hours)
|
Endothelium markers
Tidsramme: At hospital arrival (with in 2 hours)
|
Plasma sample analysed; Syndecan-1
|
At hospital arrival (with in 2 hours)
|
Endothelium markers
Tidsramme: At hospital arrival (with in 2 hours)
|
Plasma sample analysed; soluble thrombomodulin
|
At hospital arrival (with in 2 hours)
|
In hospital red blood cell transfusion requirements
Tidsramme: Within in the first 24 hours after hospital arrival
|
Amount of red blood cells transfused as registered in patient electronic records
|
Within in the first 24 hours after hospital arrival
|
In hospital plasma transfusion requirements
Tidsramme: Within in the first 24 hours after hospital arrival
|
Amount of plasma transfused as registered in patient electronic records
|
Within in the first 24 hours after hospital arrival
|
In hospital platelet transfusion requirements
Tidsramme: Within in the first 24 hours after hospital arrival
|
Amount of platelet transfused as registered in patient electronic records
|
Within in the first 24 hours after hospital arrival
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Studiestol: Christian Fenger-Eriksen, Aarhus Universityhospital
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 1-10-72-289-20
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Blood products
-
Radicle ScienceFullførtKognitiv funksjonForente stater
-
Radicle ScienceAktiv, ikke rekrutterendeSmerte | Nevropatisk smerte | Nociseptiv smerteForente stater
-
Radicle ScienceRekrutteringKognitiv funksjonForente stater
-
Michael SekelaFullførtKronisk iskemisk hjertesykdomForente stater
-
Suranaree University of TechnologyFullførtFenomenet med reduksjonen i den elektriske motstanden i de ledende kamrene, noe som gjør økningen i en ledende eiendomThailand
-
ExThera Medical Europe BVExThera Medical Corporation; Vivantes Clinic NeuköllnRekrutteringBlodstrømsinfeksjonFrankrike, Tyskland, Nederland, Østerrike, Belgia, Italia, Polen, Spania, Storbritannia
-
Ascensia Diabetes CareFullført
-
National Institute of Allergy and Infectious Diseases...FullførtKronisk granulomatøs sykdomForente stater
-
InSightecFocused Ultrasound FoundationRekruttering